The only long-term secondary prevention trial randomized children with DMD (range 9.5–13 years old) with preserved EF and no clinical evidence of CHF to afterload reduction with the ACE inhibitor perindopril versus placebo [45]. This evidence concerns the gene ACE and congestive heart failure.